7,541.90

-38.17

-0.50%

52,005.65

+235.34

+0.45%

25,155.07

-281.92

-1.11%

2,809.98

-1.86

-0.07%

4.8940

-0.0350

-0.71%

21.70

+2.28

+11.72%

3,953.70

+54.80

+1.41%

76,687.98

-1,097.38

-1.41%

Crude Oil Dec 26

95.91

-8.21

-7.89%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Vivani Medical, Inc. (VANI)

1.0950 +0.0050 (+0.46%)

As of 3:48:05 PM EST. Market Open.

Loading Chart for VANI

Chart Range Bar

Interval:

In partnership with ChartIQ

Vivani Medical Announces Participation in Upcoming Investor Conferences

Vivani Medical Announces Participation in Upcoming Investor Conferences

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani strikes reverse-merger agreement with ClearOne for BCI business

Vivani strikes reverse-merger agreement with ClearOne for BCI business

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Mobilize your Website

View Site in Mobile | Classic

Share by: